Showing results (121-130 of 151) with videos related to

Sort By:
Pageof 16
BMC Medicine|April 5, 2026
Efficacy and safety of albumin-bound paclitaxel combined with simvastatin in the second-line treatment of small cell lung cancer: a phase II randomized controlled trialMaoying Guan, Wencheng Zhao, Wengang Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|December 17, 2013
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancerBing Li, Shengxiang Ren, Xuefei Li, et al.
Oncoimmunology|January 9, 2018
Early detection of lung cancer by using an autoantibody panel in Chinese populationShengxiang Ren, Shucai Zhang, Tao Jiang, et al.
Translational Lung Cancer Research|September 21, 2020
CD39: the potential target in small cell lung cancerShanhao Chen, Shengyu Wu, Liping Zhang, et al.
Oncotargets and Therapy|March 24, 2021
Single-Cell Sequencing, an Advanced Technology in Lung Cancer ResearchHao Wang, Die Meng, Haoyue Guo, et al.
Translational Lung Cancer Research|June 15, 2026
Major histocompatibility complex II serves as a prognostic biomarker in resectable pulmonary sarcomatoid carcinoma: development of a prediction modelHao Wang, Li Ye, Xinyue Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 10, 2015
EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung CancerYan Wang, Jun Zhang, Guanghui Gao, et al.
Annals of Palliative Medicine|April 9, 2021
Research progress on the molecular mechanisms of hepatic metastasis in lung cancer: a narrative reviewXinxin Ying, Nuo Ma, Xuehan Zhang, et al.
Clinical Epidemiology|October 20, 2025
Design and Protocol of the Biobank for Metabolic Syndrome Consequences (BMSC): A Prospective Cohort Study in Northwest ChinaXue Yang, Qian Li, Yayi He, et al.
Therapeutic Advances in Medical Oncology|May 21, 2025
Efficacy and safety of distinct regimens for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review and network meta-analysisWengang Zhang, Jian Xiong, Yujie Li, et al.
Pageof 16